Osteoarthritis of the knee Musculoskeletal Diseases Osteoarthritis
Conditions
Interventions
After washout of earlier OA medications, patients were randomly allocated into two groups treated with either acetaminophen up to 4 g per day (n = 10, age 60-77 years) or rofecoxib 25 mg per day (n =
Sponsors
Merck Sharp and Dohme (MSD) (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients and healthy subjects: 20 patients fulfilled the American College of Rheumatology criteria for knee OA accompanied with joint pain (visual analogue scale [VAS] =60) were recruited to the study. For control, blood from 20 age and gender-matched healthy subjects was obtained from a local blood bank, the Blutspenderdienst Zürich. All patients signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Secondary OA as a consequence of inflammation, gout, pseudogout or tumour 2. Kidney insufficiency 3. OA-influencing concomitant diseases 4. Drug medication with opioids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The functional status of the knee joint was assessed by the Western Ontario McMaster Universities Osteoarthritis (WOMAC) questionnaire in German. Visits and measurements were scheduled upon entry (T0), month 1 (T1) and month 3 (T3). | — |
Secondary
| Measure | Time frame |
|---|---|
| The intensity of joint pain was evaluated by 100-mm visual analogue scale (VAS) at rest. Visits and measurements were scheduled upon entry (T0), month 1 (T1) and month 3 (T3). | — |
Countries
Switzerland
Outcome results
None listed